Hftor-Plus Tablet is a combination medication containing Spironolactone 50 mg and Torasemide 10 mg, primarily indicated for the management of edema associated with congestive heart failure, hepatic cirrhosis, and nephrotic syndrome. Spironolactone is a potassium-sparing diuretic that acts as an aldosterone antagonist, promoting sodium excretion while conserving potassium, thereby preventing hypokalemia. Torasemide is a loop diuretic that inhibits the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, resulting in potent diuresis and reduction of fluid overload. The synergistic effect of these agents enhances diuretic efficacy while minimizing electrolyte imbalance. Hftor-Plus is also utilized in the treatment of hypertension, particularly in patients with volume overload or resistant hypertension. The combination therapy improves patient compliance by reducing pill burden. It is contraindicated in patients with anuria, severe renal impairment, hyperkalemia, or hypersensitivity to either component. Caution is advised in patients with hepatic impairment or electrolyte disturbances. Regular monitoring of renal function, serum electrolytes, and blood pressure is recommended during therapy. Adverse effects may include dizziness, hyperkalemia, hypotension, and gastrointestinal disturbances. Hftor-Plus should be used under medical supervision to optimize therapeutic outcomes and minimize risks.